Literature DB >> 7511361

Effects of antifungal therapy on inflammation, sterilization, and histology in experimental Candida albicans meningitis.

H S Jafari1, X Sáez-Llorens, C Severien, F Parras, I Friedland, S Rinderknecht, S Ehrett, K D Olsen, C Abramowsky, G H McCracken.   

Abstract

To assess the effects of antifungal therapy on the course of Candida albicans central nervous system infection and inflammation, we inoculated intracisternally 10(5) CFU of C. albicans into rabbits. Fluconazole (10 mg/kg of body weight) or amphotericin B (1 mg/kg) was infused intravenously daily for 14 days. Treatment was initiated 24 h or 5 days after infection. Cerebrospinal fluid (CSF) was repeatedly obtained to culture the organisms, assess the level of inflammation, and measure drug concentrations. Brain tissue was obtained at the end of therapy for culture, drug concentration determinations, and histopathology. The median number of days of treatment required to sterilize CSF cultures was 4 days for fluconazole therapy and 1 day for amphotericin B therapy (P = 0.037). There was a significant reduction in tumor necrosis factor alpha and leukocyte concentrations in the CSF of animals treated early versus those in untreated control animals (P < 0.05 and P < 0.001, respectively; analysis of variance). Compared with treated animals, a higher proportion of cultured CSF samples from untreated animals were positive for Candida (P < 0.001). A cultured brain sample from 1 of the 12 animals treated early with amphotericin B was positive for C. albicans (P < 0.01 versus controls); cultures of brain samples from 3 of 12 animals treated early with fluconazole were positive, whereas cultures of brain samples from 10 of 12 controls were positive (P < 0.05). The mean density of C. albicans was lower in the single culture-positive amphotericin B recipient (1 x 10(1) CFU/g of brain tissue) than in those treated with fluconazole (1 x 10(3) CFU/g) and in controls (8 x 10(4) CFU/g). In animals treated late, the density of C. albicans in the brain in relation to the number of days of therapy was significantly lower in amphotericin B recipients than in those treated with fluconazole (P < 0.01) and untreated controls (P < 0.01; analysis of covariance). By histopathology, a larger proportion of untreated animals compared with those treated early demonstrated features of severe infection such as perivasculitis, ventriculitis, and evidence of fungal organisms. Compared with amphotericin B-treated rabbits, those given fluconazole had a trend toward more severe pathologic lesions. Reduced susceptibility to both fluconazole and amphotericin B was observed in the C. albicans organisms isolated from the brain of one fluconazole-treated animal. These data suggest that amphotericin B is the preferred treatment for C. albicans infections of the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7511361      PMCID: PMC284401          DOI: 10.1128/AAC.38.1.83

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  Characteristics of experimental Candida albicans infection of the central nervous system in rabbits.

Authors:  H S Jafari; X Sáez-Llorens; E Grimprel; J C Argyle; K D Olsen; G H McCracken
Journal:  J Infect Dis       Date:  1991-08       Impact factor: 5.226

2.  Penetration of imidazoles and triazoles into cerebrospinal fluid of rabbits.

Authors:  J R Perfect; D T Durack
Journal:  J Antimicrob Chemother       Date:  1985-07       Impact factor: 5.790

3.  SCH-39304 in prevention and treatment of disseminated candidiasis in persistently granulocytopenic rabbits.

Authors:  T J Walsh; J W Lee; J Lecciones; P Kelly; J Peter; V Thomas; J Bacher; P A Pizzo
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

4.  Comparison of in vitro cell cytotoxic assays for tumor necrosis factor.

Authors:  D A Flick; G E Gifford
Journal:  J Immunol Methods       Date:  1984-03-30       Impact factor: 2.303

5.  Comparison of fluconazole and amphotericin B for treatment of disseminated candidiasis and endophthalmitis in rabbits.

Authors:  S G Filler; M A Crislip; C L Mayer; J E Edwards
Journal:  Antimicrob Agents Chemother       Date:  1991-02       Impact factor: 5.191

6.  Disseminated fungal infections in very low-birth-weight infants: clinical manifestations and epidemiology.

Authors:  J E Baley; R M Kliegman; A A Fanaroff
Journal:  Pediatrics       Date:  1984-02       Impact factor: 7.124

7.  Effects of amphotericin B and fluconazole on the extracellular and intracellular growth of Candida albicans.

Authors:  E W van Etten; N E van de Rhee; K M van Kampen; I A Bakker-Woudenberg
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

8.  Candidal infection in the central nervous system.

Authors:  S A Lipton; W F Hickey; J H Morris; J Loscalzo
Journal:  Am J Med       Date:  1984-01       Impact factor: 4.965

9.  Systemic Candida infections in infants in intensive care nurseries: high incidence of central nervous system involvement.

Authors:  R G Faix
Journal:  J Pediatr       Date:  1984-10       Impact factor: 4.406

10.  Effect of probenecid on cerebrospinal fluid concentrations of penicillin and cephalosporin derivatives.

Authors:  R G Dacey; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1974-10       Impact factor: 5.191

View more
  7 in total

Review 1.  Nanoparticle transport across the blood brain barrier.

Authors:  Andreas M Grabrucker; Barbara Ruozi; Daniela Belletti; Francesca Pederzoli; Flavio Forni; Maria Angela Vandelli; Giovanni Tosi
Journal:  Tissue Barriers       Date:  2016-02-25

2.  Compartmental pharmacokinetics and tissue distribution of multilamellar liposomal nystatin in rabbits.

Authors:  A H Groll; D Mickiene; K Werner; R Petraitiene; V Petraitis; M Calendario; A Field-Ridley; J Crisp; S C Piscitelli; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

3.  Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits.

Authors:  R Petraitiene; V Petraitis; A H Groll; M Candelario; T Sein; A Bell; C A Lyman; C L McMillian; J Bacher; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

4.  Refractory candidal meningitis in an immunocompromised patient cured by caspofungin.

Authors:  Kung-Hung Liu; Chi-Jung Wu; Chen-Hsi Chou; Hsin-Chun Lee; Nan-Yao Lee; Shao-Tsung Hung; Wen-Chien Ko
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

5.  The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates.

Authors:  William W Hope; Diana Mickiene; Vidmantas Petraitis; Ruta Petraitiene; Amy M Kelaher; Joanna E Hughes; Margaret P Cotton; John Bacher; James J Keirns; Donald Buell; Gloria Heresi; Daniel K Benjamin; Andreas H Groll; George L Drusano; Thomas J Walsh
Journal:  J Infect Dis       Date:  2008-01-01       Impact factor: 5.226

6.  Self-assembled cationic peptide nanoparticles as an efficient antimicrobial agent.

Authors:  Lihong Liu; Kaijin Xu; Huaying Wang; P K Jeremy Tan; Weimin Fan; Subbu S Venkatraman; Lanjuan Li; Yi-Yan Yang
Journal:  Nat Nanotechnol       Date:  2009-06-28       Impact factor: 39.213

7.  Recurrent Candida albicans Ventriculitis Treated with Intraventricular Liposomal Amphotericin B.

Authors:  Demet Toprak; Sevliya Öcal Demir; Eda Kepenekli Kadayifci; Özden Türel; Ahmet Soysal; Mustafa Bakir
Journal:  Case Rep Infect Dis       Date:  2015-10-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.